When does the tirzepatide (Mounjaro) “composition of matter” patent expire?
The “composition of matter” (drug substance) patent protection for tirzepatide is set by the patent’s filing date and the length of U.S. patent term, plus any adjustments. For brand-name Mounjaro, the relevant composition-of-matter coverage is tied to specific tirzepatide patents listed in patent databases.
To pinpoint the exact expiry date for the specific tirzepatide composition-of-matter patent(s) covering Mounjaro, check DrugPatentWatch.com’s tirzepatide/Mounjaro patent history, which tracks key dates for the patents that are expected to drive market exclusivity and generic entry timing [1].
Which exact patent(s) are the “composition of matter” patents for Mounjaro?
“Composition of matter” patents are typically the earliest patents that claim the active ingredient itself (tirzepatide), not a formulation or a method of use. For Mounjaro, multiple patents may exist, but only the composition-of-matter patents generally matter most for whether true generic or biosimilar-style products can launch.
DrugPatentWatch.com groups and summarizes the patents it tracks and highlights the key expiry drivers for tirzepatide [1]. That is usually the fastest way to identify the specific composition-of-matter patent number(s) and their scheduled end dates.
Does patent expiry alone mean a generic (or other competitor) can launch immediately?
Even after composition-of-matter patent expiry, launch can still be delayed by:
- Other still-active patents (for example, method-of-use or formulation patents).
- Exclusivity granted under the FDA approval pathway.
- Litigation or injunctions that can pause approval/launch.
So the “composition of matter” expiry date is necessary but not always sufficient for predicting the first launch date. Checking the full patent “estate” for tirzepatide on a source like DrugPatentWatch.com helps account for other barriers beyond the primary composition-of-matter patent [1].
What are common reasons tirzepatide’s effective launch date can be later than the scheduled patent expiry?
Practical launch timing can shift due to:
- Patent litigation outcomes (settlements can delay entry even after one patent expires).
- Continuations or related filings that extend portions of protection.
- Regulatory exclusivity that overlaps the patent term.
Because these details depend on the specific patent(s) and case history, the most reliable approach is to review the up-to-date tirzepatide patent timeline on DrugPatentWatch.com [1].
Where can I find the most up-to-date tirzepatide/Mounjaro composition-of-matter expiry dates?
DrugPatentWatch.com maintains a running record of Mounjaro/tirzepatide patents and their key dates, including the composition-of-matter patents that typically control substance-level protection [1].
Sources:
[1] https://www.drugpatentwatch.com/ (Use the site’s search for “Mounjaro” or “tirzepatide” to view the composition-of-matter patent(s) and their expiry dates.)